French immunotherapy company OSE Immunotherapeutics (Euronext Paris: OSE) has appointed Dr Sonya Montgomery as chief development officer. She will serve on the OSE executive committee in a strategic move that will enhance the company’s development capabilities.
OSE noted that Dr Montgomery brings over two decades of experience leading R&D strategies at major life science companies. She will oversee development activities for the company’s key assets and the strategic development of the pre-clinical and clinical product portfolio, and coordinate development efforts across manufacturing, supply, translational & biomarker development, alliance, and medico-marketing teams.
Business background
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze